Statins, emblematic of HMG-CoA reductase inhibitors, decrease LDL-C synthesis by suppressing HMGCR expression and are the primary choice for cardiovascular disease prevention in clinical settings. The gene discussed is HMGCR; the disease is cardiovascular disorder.